Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Lung Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Journal Scan / Research · November 23, 2021

89Zr-Pembrolizumab Imaging to Assess PD-1 Blockade Response

Annals of Oncology


Additional Info

Annals of Oncology
89Zr-Pembrolizumab Imaging as a Non-Invasive Approach to Assess Clinical Response to PD-1 Blockade in Cancer
Ann. Oncol 2021 Nov 01;[EPub Ahead of Print], IC Kok, JA Hooiveld, PP van de Donk, D Giesen, EL van der Veen, MNL Hooge, AH Brouwers, TJN Hiltermann, AJ van der Wekken, LBM Hijmering-Kappelle, W Timens, SG Elias, GAP Hospers, HJM Groen, W Uyterlinde, B van der Hiel, JB Haanen, DJA de Groot, M Jalving, EGE de Vries

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading